Drug intelligence / Profile preview

BMS-833923 + bortezomib

Development stage: Unknown
Lead developer: Exelixis
Modality: Small Molecules
Administration: Oral (BMS-833923), Intravenous (bortezomib)

Overview

BMS-833923 + bortezomib is an investigational drug combination studied in early-phase clinical trials, primarily targeting relapsed or refractory multiple myeloma. BMS-833923 (also called XL139) is a potent, orally active, small molecule antagonist of Smoothened, a key component of the Hedgehog signaling pathway implicated in cancer cell proliferation. Bortezomib is a reversible inhibitor of the 26S proteasome, leading to the accumulation of misfolded proteins and apoptosis in cancer cells. This combination is hypothesized to have synergistic anti-tumor effects due to complementary mechanisms of targeting cell survival and proliferation pathways[1][2][5].

Other names: BMS-833923 + bortezomib

Targets

26S proteasomeSMO (Smoothened)

Beyond the preview

Go deeper on BMS-833923 + bortezomib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-833923 + bortezomib.

Explore the full profile